Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Yannis Metaxas, Martin Früh, E.I. Eboulet, Federica Grosso, Miklos Pless, Paolo Andrea Zucali, Giovanni Luca Ceresoli, Michael Mark, Martina Schneider, Antonio Maconi, Matteo Perrino, Christine Biaggi‐Rudolf, Patrizia Froesch, Sabine Schmid, Christine Waibel, Christina Appenzeller, Daniel Rauch, Roger von Moos